Vir Biotechnology, Inc.
Vir Biotechnology is a clinical-stage biopharmaceutical company that discovers and develops medicines for serious infectious diseases and cancer. Its clinical programs include tobevibart and elebsiran for chronic hepatitis delta, HIV broadly neutralizing antibodies, and dual-masked T-cell engagers for solid tumors. The tumor candidates in Phase 1 target PSMA, HER2 and EGFR; Vir is also advancing preclinical T-cell engagers and making preclinical influenza antibodies, antibody drug conjugates and coronavirus monoclonal antibodies available for external partnerships. Vir makes potential medicines using antibody discovery and engineering, its dAIsY artificial intelligence platform and the PRO-XTEN masking platform, which it in-licensed from Sanofi. Its work spans research, development and clinical testing, with manufacturing and development support from contract organizations. Vir Biotechnology is headquartered in San Francisco.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Vir Biotechnology (NASDAQ:VIR) plans a public stock offering, with underwriters having a 30-day option to buy 15% more shares. The offering is subject to market conditions. The company focuses on infectious diseases and cancer treatments. Leerink Partners, Morgan Stanley, and Evercore ISI are bookrunning managers.
Vir Biotechnology reported that its monthly two-drug injection for hepatitis delta made the virus undetectable in 79% of patients in a phase 3 trial. The trial's main goal, undetectable virus combined with normal liver enzyme levels, was reached by 44% of treated patients. The results have not yet been peer-reviewed. The company plans to seek FDA approval in mid-2027.
Vir Biotechnology's hepatitis delta drug combination met all Phase 3 trial endpoints, with 79% of patients achieving undetectable virus levels. Shares rose 11.8% to $13.65 on November 9. The company plans a mid-2027 FDA filing and has a €550M European licensing deal with Norgine. Vir has $901M in cash and expects funding to last into 2028. Competitors include Gilead and Mirum Pharmaceuticals.
Over the past 7 days, AlphAI's AI scored 32 news stories mentioning VIR (Vir Biotechnology, Inc.). Coverage has skewed bullish: 30 bullish, 1 neutral, and 1 bearish.
Recent VIR coverage spans financial news, market movers and corporate actions.
In the last 30 days, VIR insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($42K). The most active reporter was de Verneuil Vanina, EVP, General Counsel, Corp Sec, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The offering introduces dilution risk, likely pressuring the share price.
Positive Phase 3 data likely lifts expectations for FDA approval and could boost the stock.
Positive trial data and licensing agreement drive strong upside potential.
Analyst upgrade and higher price target suggest upside potential for VIR.
Analyst upgrade suggests upside potential for VIR.
AlphAI scores every news story that mentions VIR with an AI model for sentiment and relevance, and aggregates insider trades from Vir Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vir Biotechnology (NASDAQ:VIR) plans a public stock offering, with underwriters having a 30-day option to buy 15% more shares. The offering is subject to market conditions. The company focuses on infectious diseases and cancer treatments. Leerink Partners, Morgan Stanley, and Evercore ISI are bookrunning managers.
Vir Biotechnology reported that its monthly two-drug injection for hepatitis delta made the virus undetectable in 79% of patients in a phase 3 trial. The trial's main goal, undetectable virus combined with normal liver enzyme levels, was reached by 44% of treated patients. The results have not yet been peer-reviewed. The company plans to seek FDA approval in mid-2027.
Vir Biotechnology's hepatitis delta drug combination met all Phase 3 trial endpoints, with 79% of patients achieving undetectable virus levels. Shares rose 11.8% to $13.65 on November 9. The company plans a mid-2027 FDA filing and has a €550M European licensing deal with Norgine. Vir has $901M in cash and expects funding to last into 2028. Competitors include Gilead and Mirum Pharmaceuticals.
Morgan Stanley kept Vir Biotechnology at Overweight, raising its price target to $28 from $25, citing a 105.2% upside from the Nov 9 close of $13.64. Recent analyst targets range from $22 to $25.
Evercore ISI Group reaffirmed its Outperform rating for Vir Biotechnology and increased its price target to $25 from $22, representing a 13.6% rise. This target suggests an 83.2% upside from the Nov 9 closing price of $13.64.
Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.
Vir Biotechnology (VIR) shares rose 13.92% to $13.91 after reporting Phase 2 trial data showing 100% of patients achieved undetectable hepatitis delta virus levels. 89% of patients showed improved or stable liver stiffness. The stock's 52-week range is $5.22 to $14.38, with volume at 4.08 million shares. The company plans a Phase 3 ECLIPSE program with a 2027 regulatory filing.
Vir Biotechnology, Inc. (VIR) filed an SEC Form 8-K — Other Events. Item 7.01 Regulation FD Disclosure. Vir Biotechnology, Inc. (the Company) is holding a virtual investor conference call at 5:30 a.m. PT / 8:30 a.m. ET on November 9, 2026, to discuss the topline results from the pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly subcutan
Vir Biotechnology (VIR) reported that its Phase 2 SOLSTICE trial showed undetectable HDV RNA in all 28 patients after 96 weeks of treatment with elebsiran and tobevibart. All 10 eligible patients maintained a virologic response for at least 12 weeks post-treatment. The combination therapy received Breakthrough Therapy and Fast Track designations in the U.S. and PRIME and orphan drug designations in Europe. VIR shares rose 15.23% in premarket trading.
Moderna (MRNA), Xeris Biopharma (XERS), and Vir Biotechnology (VIR) reached 52-week highs. MRNA rose 5% after Q3 results beat expectations, with price targets raised by TD Cowen, RBC, and BofA. XERS surged 16% on raised 2030 revenue outlook. VIR climbed 11% ahead of Phase 2 trial data. All stocks saw bullish retail sentiment on Stocktwits.
